| Tebas, Pablo |
NCT04636437: Doravirine for Persons With Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide |
|
|
| Active, not recruiting | 4 | 222 | US | Doravirine 100 Mg, Tenofovir alafenamide/emtricitabine, tenofovir alafenamide/lamivudine, Integrase strand transfer inhibitors, tenofovir disproxil fumarate/emtricitabine, tenofovir disproxil fumarate/lamivudine | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 11/24 | 11/24 | | |
NCT04060316: GLS-1200 Topical Nasal Spray to Prevent Sinusitis After Endoscopic Sinus Surgery |
|
|
| Not yet recruiting | 2 | 99 | US | GLS-1200, Placebo, Sterile Saline | GeneOne Life Science, Inc. | Sinusitis Chronic | 12/23 | 09/24 | | |
NCT03739996: Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1 |
|
|
| Completed | 2 | 75 | US | Oral Cabotegravir (CAB), Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Long-Acting Injectable Cabotegravir (CAB LA), VRC07-523LS, VRC-HIVMAB075-00-AB, Standard of Care (SOC) Oral ART | National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare | HIV Infections | 04/24 | 04/24 | | |
BEAT-2, NCT03588715: Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074 |
|
|
| Active, not recruiting | 1 | 15 | US | Pegylated Interferon alpha 2b (peg-IFN-α2b), Pegintron, 3BNC117 + 10-1074, Broadly Neutralizing Antibodies | Luis Montaner, University of Pennsylvania, Philadelphia Fight, Rockefeller University, Merck Sharp & Dohme LLC, National Institute of Allergy and Infectious Diseases (NIAID) | HIV, HIV/AIDS, HIV-1 Infection | 12/21 | 10/22 | | |
| Terminated | 1 | 52 | US | SAR441236, Placebo | National Institute of Allergy and Infectious Diseases (NIAID), Sanofi, ModeX Therapeutics | HIV-1-infection | 04/22 | 04/22 | | |
| Active, not recruiting | 1 | 61 | US | dMAb AZD5396, dMAb AZD8076, CELLECTRA™ 2000 with Side Port needle, OpBlock 0078 Electroporation device, Hylenex, CELLECTRA™ 2000 with Side Port needle, OpBlock 0070 Electroporation device | Pablo Tebas, The Wistar Institute, AstraZeneca, Inovio Pharmaceuticals | Healthy Volunteers | 09/25 | 09/25 | | |
| Active, not recruiting | 1 | 12 | US | CD4 CAR+CCR5 ZFN T-cells | University of Pennsylvania | Hiv | 12/26 | 12/27 | | |
NCT00031408: Consent for Use of Stored Patient Specimens for Future Testing |
|
|
| Recruiting | N/A | 30000 | US | | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 12/27 | 12/27 | | |
| Coukos, George |
NCT02659384 / 2015-004601-17: Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer |
|
|
| Completed | 2 | 122 | Europe | Bevacizumab, Avastin, atezolizumab, acetylsalicylic acid, placebo | European Organisation for Research and Treatment of Cancer - EORTC | Ovarian Neoplasms | 06/21 | 03/22 | | |
ATATIL, NCT03475134: TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL) |
|
|
| Active, not recruiting | 1 | 18 | Europe | TIL, Cyclophosphamide, Fludarabine, Interleukin-2, Nivolumab | Centre Hospitalier Universitaire Vaudois | Metastatic Melanoma | 06/26 | 06/26 | | |
| Active, not recruiting | 1 | 42 | Europe | NeoTIL, Cyclophosphamide, Fludarabine, Interleukin-2, Radiotherapy | Centre Hospitalier Universitaire Vaudois | Solid Tumor, Adult | 11/27 | 11/27 | | |
NCT01000259: Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer |
|
|
| Recruiting | N/A | 174 | US | Laboratory Biomarker Analysis | Gynecologic Oncology Group, National Cancer Institute (NCI) | Stage IIIA Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer | 01/00 | | | |
